# A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

Source: https://onco.cc/trials/nct03526835/  
OnCo record `nct03526835` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Petosemtamab, Pembrolizumab, FOLFIRI in colorectal cancer and head and neck squamous cell carcinoma, run by Merus B.V., now recruiting.

## Summary

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT03526835 by Merus B.V., with 560 participants planned, started 2018-05-02 and due to reach its primary completion in 2028-05. Interventions recorded: MCLA-158, MCLA-158 + Pembrolizumab, MCLA-158 + FOLFIRI, MCLA-158 + FOLFOX. Conditions listed: Advanced/Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer, Gastroesophageal-junction Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT03526835
- Phase: 1/2
- Setting: Phase 1/2 Dose Escalation and Cohort Expansion Study Evaluating MCLA-158 (Petosemtamab) as Single Agent or in Combination in Advanced Solid Tumors
- Sponsor: Merus B.V.
- Enrolled: 560

## Sources

- ClinicalTrials.gov NCT03526835: https://clinicaltrials.gov/study/NCT03526835

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- drugs: [FOLFIRI (5-FU, leucovorin, irinotecan)](https://onco.cc/drugs/folfiri/), [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Pembrolizumab](https://onco.cc/drugs/pembrolizumab/), [Petosemtamab](https://onco.cc/drugs/petosemtamab/)
- companies: [Genmab](https://onco.cc/companies/genmab/)

---
JSON: https://onco.cc/api/v1/entities/nct03526835.json